PMID- 12411121
OWN - NLM
STAT- MEDLINE
DCOM- 20021122
LR  - 20121115
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 115
IP  - 9
DP  - 2002 Sep
TI  - Protection of retinal ganglion cells against glaucomatous neuropathy by 
      neurotrophin-producing, genetically modified neural progenitor cells in a rat 
      model.
PG  - 1394-400
AB  - OBJECTIVE: To investigate in vivo survival of retinal ganglion cells (RGCs) after 
      partial blockage of optic nerve (ON) axoplasmic flow by sub-retinal space or 
      vitreous cavity injection of brain-derived neural factor (BDNF) produced by 
      genetically modified neural progenitor cells (NPCs). METHODS: Adult 
      Sprague-Dawley (SD) rat RGCs were labeled with granular blue (GB) applied to 
      their main targets in the brain. Seven days later, the left ON was intra-obitally 
      crushed with a 40 g power forceps to partially block ON axoplasmic flow. Animals 
      were randomized to three groups. The left eye of each rat received a sham 
      injection, NPCs injection or an injection of genetically modified neural 
      progenitors producing BDNF (BDNF-NPCs). Seven, 15 and 30 days after ON crush, 
      retinas were examined under a fluorescence microscope. By calculating and 
      comparing the average RGCs densities and RGC apoptosis density, RGC survival was 
      estimated and the neuro-protective effect of transplanted cells was evaluated. 
      RESULTS: Seven, 15 and 30 days after crush, in the intra-vitreous injection 
      group, mean RGC densities had decreased to 1885 +/- 68, 1562 +/- 20, 1380 +/- 7 
      and 1837 +/- 46, 1561 +/- 58, 1370 +/- 16, respectively with sham injection or 
      neural progenitors injection. However, RGCs density in the groups treated with 
      intra-vitreous injection of BDNF-NPC was 2101 +/- 15, 1809 +/- 19 and 1625 +/- 
      34. Similar results were found in groups after sub-retinal injection. Higher 
      densities were observed in groups treated with BDNF-NPCs. There were 
      statistically significant differences among groups through nonparametric tests 
      followed by the Mann-Whitely test. RGC apoptosis density in BDNF-NPC at each 
      follow-up time was less than in other groups. CONCLUSIONS: A continuous supply of 
      neurotrophic factors by the injection of genetically modified neural progenitors 
      presents a highly effective approach to counteract optic neuropathy and RGC 
      degeneration after partial ON axoplasmic flow blockage.
FAU - Wang, Ningli
AU  - Wang N
AD  - Zhongshan Ophthalmic Center, Zhongshan University, Guangzhou 510060, China. 
      ningliw@hotmail.com
FAU - Zeng, Mingbing
AU  - Zeng M
FAU - Ruan, Yiwen
AU  - Ruan Y
FAU - Wu, Heping
AU  - Wu H
FAU - Chen, Jingchang
AU  - Chen J
FAU - Fan, Zhigang
AU  - Fan Z
FAU - Zhen, Huling
AU  - Zhen H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Axonal Transport
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cell Survival
MH  - Gene Transfer Techniques
MH  - *Genetic Therapy
MH  - Glaucoma/*therapy
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Retinal Ganglion Cells/*cytology
MH  - Stem Cells/*physiology
MH  - Vitreous Body/metabolism
EDAT- 2002/11/02 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/11/02 04:00
PHST- 2002/11/02 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/11/02 04:00 [entrez]
PST - ppublish
SO  - Chin Med J (Engl). 2002 Sep;115(9):1394-400.